within Pharmacolibrary.Drugs.ATC.J;

model J01CR03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00013333333333333334,
    adminDuration  = 600,
    adminMass      = 3000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.007,
    k12             = 6,
    k21             = 6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01CR03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ticarcillin is a broad-spectrum penicillin antibiotic that is primarily used in combination with a beta-lactamase inhibitor (typically clavulanic acid) to extend its activity against beta-lactamase-producing organisms. The combination is indicated for the treatment of various serious bacterial infections, including lower respiratory tract, urinary tract, intra-abdominal, and gynecological infections. In many countries, this formulation has been discontinued or is used less commonly today due to the development of newer agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for ticarcillin in combination with clavulanic acid in healthy adults, intravenous administration. Data are estimated from historical single-dose studies and reviews, as no recent publications with detailed compartmental PK parameters are available.</p><h4>References</h4><ol><li><p>Reed, MD (1998). Rational prescribing of extended-spectrum penicillin beta-lactamase inhibitor combinations: focus on ticarcillin/clavulanic acid. <i>The Annals of pharmacotherapy</i> 32(1) S17–S21. DOI:<a href=&quot;https://doi.org/10.1177/106002809803200105&quot;>10.1177/106002809803200105</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9475835/&quot;>https://pubmed.ncbi.nlm.nih.gov/9475835</a></p></li><li><p>Hart, SM, &amp; Bailey, EM (1996). A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations. <i>The Annals of pharmacotherapy</i> 30(10) 1130–1140. DOI:<a href=&quot;https://doi.org/10.1177/106002809603001013&quot;>10.1177/106002809603001013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8893121/&quot;>https://pubmed.ncbi.nlm.nih.gov/8893121</a></p></li><li><p>Wilson, WD, et al., &amp; Pryor, P (1991). Pharmacokinetics and bioavailability of ticarcillin and clavulanate in foals after intravenous and intramuscular administration. <i>Journal of veterinary pharmacology and therapeutics</i> 14(1) 78–89. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2885.1991.tb00807.x&quot;>10.1111/j.1365-2885.1991.tb00807.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2038098/&quot;>https://pubmed.ncbi.nlm.nih.gov/2038098</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01CR03;
